UPB
Upstream Bio, Inc.
Price Chart
Latest Quote
$6.15
+0.23 (+3.89%)
Current Price
| Previous Close | $5.92 |
| Open | $5.94 |
| Day High | $6.33 |
| Day Low | $5.88 |
| Volume | 819,883 |
Stock Information
| Shares Outstanding | 54.42M |
| Total Debt | $1.11M |
| Cash Equivalents | $294.58M |
| Revenue | $3.32M |
| Net Income | $-156.76M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $334.68M |
| EPS (TTM) | $-2.90 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $28.70M |
| Sales | $3.32M |
| Income | $-156.76M |
| Book/sh | $6.26 |
| Cash/sh | $5.41 |
| Employees | 75 |
Financial Ratios
| Quick Ratio | 21.74 |
| Current Ratio | 23.14 |
| Debt/Eq | 0.37 |
Returns & Margins
| ROA | -27.76% |
| ROE | -41.83% |
| Gross Margin | 100.00% |
| Operating Margin | -4218.09% |
Ownership
| Insider Ownership | 14.88% |
| Institutional Ownership | 90.11% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.13 |
| P/S | 100.75 |
| P/B | 0.98 |
Analyst Data
| Recommendation | buy |
| Target Price | $38.25 |
Technical Indicators
| SMA20 | $7.29 |
| SMA50 | $8.58 |
| SMA200 | $17.66 |
| RSI | 23.86 |
| ATR | 0.5047 |
| Shares Float | 34.97M |
| Short Float | 10.32% |
| Short Ratio | 7.07 |
| Rel Volume | 1.31 |
Performance History
| Week | -2.07% |
| Month | -27.73% |
| Quarter | -29.02% |
| 6 Months | -77.39% |
| YTD | -77.28% |
| Year | -44.94% |
| 10 Years | -72.05% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $6.15 | 827,851 |
| 2026-06-16 | $5.92 | 519,900 |
| 2026-06-15 | $6.10 | 681,400 |
| 2026-06-12 | $6.10 | 1,432,200 |
| 2026-06-11 | $6.38 | 833,100 |
| 2026-06-10 | $6.28 | 450,100 |
| 2026-06-09 | $6.69 | 500,500 |
| 2026-06-08 | $6.45 | 783,900 |
| 2026-06-05 | $7.05 | 672,400 |
| 2026-06-04 | $7.43 | 688,200 |
| 2026-06-03 | $7.63 | 666,400 |
| 2026-06-02 | $7.25 | 632,600 |
| 2026-06-01 | $8.08 | 595,100 |
| 2026-05-29 | $8.36 | 499,100 |
| 2026-05-28 | $8.32 | 320,800 |
| 2026-05-27 | $8.26 | 420,400 |
| 2026-05-26 | $8.21 | 593,000 |
| 2026-05-22 | $8.37 | 354,400 |
| 2026-05-21 | $8.46 | 597,500 |
| 2026-05-20 | $8.41 | 593,000 |
| 2026-05-19 | $8.03 | 982,500 |
| 2026-05-18 | $8.51 | 511,300 |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-13T12:20:03Z
Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-03-27T13:46:25Z
Here Are Fridayâs Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
24/7 Wall St. âĸ 2026-03-27T12:04:16Z
Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%
MarketBeat âĸ 2026-02-16T00:11:13Z
Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth
Simply Wall St. âĸ 2026-02-15T13:03:42Z
Upstream Bioâs stock drops 47% on verekitug Phase II asthma data
Clinical Trials Arena âĸ 2026-02-12T12:55:05Z
Upstream Bio Crashes After Asthma Drug Succeeds â With The Wrong Dose
Investor's Business Daily âĸ 2026-02-11T21:04:23Z
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill
BioPharma Dive âĸ 2026-02-11T09:33:00Z
Upstream Bio (UPB): Evaluating Valuation After 10% Share Price Surge
Simply Wall St. âĸ 2025-11-26T04:28:53Z
Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TSLP Receptor Targeting
Insider Monkey âĸ 2025-10-16T20:33:14Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,854,000 | $2,370,000 | $2,380,000 | $1,212,000 |
| Operating Revenue | $2,854,000 | $2,370,000 | $2,380,000 | $1,212,000 |
| Expenses | ||||
| Total Expenses | $163,215,000 | $80,134,000 | $42,494,000 | $25,121,000 |
| Other Income Expense | $-15,000 | $2,835,000 | $15,412,000 | $-164,000 |
| Other Non Operating Income Expenses | $-15,000 | $2,835,000 | $15,412,000 | $-164,000 |
| Net Non Operating Interest Income Expense | $16,933,000 | $12,123,000 | $4,165,000 | $205,000 |
| Operating Expense | $163,215,000 | $80,134,000 | $42,494,000 | $25,121,000 |
| General And Administrative Expense | $26,409,000 | $17,168,000 | $10,695,000 | $6,464,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-143,443,000 | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Net Interest Income | $16,933,000 | $12,123,000 | $4,165,000 | $205,000 |
| Interest Income | $16,933,000 | $12,123,000 | $4,165,000 | $205,000 |
| Normalized Income | $-143,443,000 | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Net Income From Continuing And Discontinued Operation | $-143,443,000 | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Total Operating Income As Reported | $-160,361,000 | $-77,764,000 | $-40,114,000 | $-23,909,000 |
| Net Income Common Stockholders | $-143,443,000 | $-76,395,000 | $-38,255,000 | $-23,868,000 |
| Net Income | $-143,443,000 | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Net Income Including Noncontrolling Interests | $-143,443,000 | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Net Income Continuous Operations | $-143,443,000 | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Pretax Income | $-143,443,000 | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Interest Income Non Operating | $16,933,000 | $12,123,000 | $4,165,000 | $205,000 |
| Operating Income | $-160,361,000 | $-77,764,000 | $-40,114,000 | $-23,909,000 |
| Per Share | ||||
| Diluted EPS | $-2.64 | $-1.17 | $-1.05 | $-0.66 |
| Basic EPS | $-2.64 | $-1.17 | $-1.05 | $-0.66 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-160,173,000 | $-77,675,000 | $-40,054,000 | $-23,902,000 |
| Reconciled Depreciation | $188,000 | $89,000 | $60,000 | $7,000 |
| EBITDA (Bullshit earnings) | $-160,173,000 | $-77,675,000 | $-40,054,000 | $-23,902,000 |
| EBIT | $-160,361,000 | $-77,764,000 | $-40,114,000 | $-23,909,000 |
| Diluted Average Shares | $54,237,750 | $53,603,398 | $36,323,322 | $36,323,322 |
| Basic Average Shares | $54,237,750 | $53,603,398 | $36,323,322 | $36,323,322 |
| Diluted NI Availto Com Stockholders | $-143,443,000 | $-76,395,000 | $-38,255,000 | $-23,868,000 |
| Research And Development | $136,806,000 | $62,966,000 | $31,799,000 | $18,657,000 |
| Selling General And Administration | $26,409,000 | $17,168,000 | $10,695,000 | $6,464,000 |
| Other Gand A | $11,221,000 | $6,326,000 | $4,343,000 | $2,728,000 |
| Salaries And Wages | $15,188,000 | $10,842,000 | $6,352,000 | $3,736,000 |
| Preferred Stock Dividends | - | $13,589,000 | $17,718,000 | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $339,771,000 | $469,852,000 | $-123,126,000 | $-106,155,000 |
| Total Assets | $353,772,000 | $481,719,000 | $117,198,000 | $18,478,000 |
| Total Non Current Assets | $1,975,000 | $2,559,000 | $202,000 | $171,000 |
| Other Non Current Assets | $194,000 | $194,000 | - | $7,000 |
| Current Assets | $351,797,000 | $479,160,000 | $116,996,000 | $18,307,000 |
| Other Current Assets | $727,000 | $494,000 | $370,000 | $233,000 |
| Prepaid Assets | $7,240,000 | $7,035,000 | $6,580,000 | $611,000 |
| Receivables | $2,321,000 | $1,180,000 | $236,000 | $412,000 |
| Accrued Interest Receivable | $1,653,000 | $567,000 | $138,000 | $0 |
| Accounts Receivable | $668,000 | $613,000 | $98,000 | $412,000 |
| Cash Cash Equivalents And Short Term Investments | $341,509,000 | $470,451,000 | $109,810,000 | $17,051,000 |
| Cash And Cash Equivalents | $101,578,000 | $325,892,000 | $25,833,000 | $17,051,000 |
| Debt | ||||
| Total Debt | $1,269,000 | $1,834,000 | $45,000 | $94,000 |
| Long Term Debt And Capital Lease Obligation | $549,000 | $1,130,000 | $0 | $7,000 |
| Current Debt And Capital Lease Obligation | $720,000 | $704,000 | $45,000 | $87,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $14,001,000 | $11,867,000 | $240,324,000 | $124,633,000 |
| Total Non Current Liabilities Net Minority Interest | $549,000 | $1,130,000 | $233,809,000 | $119,777,000 |
| Current Liabilities | $13,452,000 | $10,737,000 | $6,515,000 | $4,856,000 |
| Payables And Accrued Expenses | $8,540,000 | $7,336,000 | $4,302,000 | $3,876,000 |
| Payables | $2,726,000 | $4,041,000 | $1,990,000 | $712,000 |
| Accounts Payable | $2,726,000 | $4,041,000 | $1,990,000 | $712,000 |
| Equity | ||||
| Common Stock Equity | $339,771,000 | $469,852,000 | $-123,126,000 | $-106,155,000 |
| Total Equity Gross Minority Interest | $339,771,000 | $469,852,000 | $-123,126,000 | $-106,155,000 |
| Stockholders Equity | $339,771,000 | $469,852,000 | $-123,126,000 | $-106,155,000 |
| Gains Losses Not Affecting Retained Earnings | $530,000 | $-25,000 | $21,000 | $0 |
| Other Equity Adjustments | $530,000 | $-25,000 | $21,000 | - |
| Retained Earnings | $-334,223,000 | $-190,780,000 | $-127,974,000 | $-107,437,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $233,809,000 | $119,770,000 |
| Other | ||||
| Ordinary Shares Number | $54,237,750 | $53,603,398 | $51,341,695 | $51,341,695 |
| Share Issued | $54,237,750 | $53,603,398 | $51,341,695 | $51,341,695 |
| Tangible Book Value | $339,771,000 | $469,852,000 | $-123,126,000 | $-106,155,000 |
| Invested Capital | $339,771,000 | $469,852,000 | $-123,126,000 | $-106,155,000 |
| Working Capital | $338,345,000 | $468,423,000 | $110,481,000 | $13,451,000 |
| Capital Lease Obligations | $1,269,000 | $1,834,000 | $45,000 | $94,000 |
| Total Capitalization | $339,771,000 | $469,852,000 | $-123,126,000 | $-106,155,000 |
| Additional Paid In Capital | $673,410,000 | $660,604,000 | $4,824,000 | $1,279,000 |
| Capital Stock | $54,000 | $53,000 | $3,000 | $3,000 |
| Common Stock | $54,000 | $53,000 | $3,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $549,000 | $1,130,000 | $0 | $7,000 |
| Current Capital Lease Obligation | $720,000 | $704,000 | $45,000 | $87,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,192,000 | $2,697,000 | $2,168,000 | $893,000 |
| Current Accrued Expenses | $5,814,000 | $3,295,000 | $2,312,000 | $3,164,000 |
| Net PPE | $1,781,000 | $2,365,000 | $202,000 | $164,000 |
| Accumulated Depreciation | $-344,000 | $-156,000 | $-67,000 | $-7,000 |
| Gross PPE | $2,125,000 | $2,521,000 | $269,000 | $171,000 |
| Leases | $87,000 | $71,000 | $27,000 | $18,000 |
| Other Properties | $1,222,000 | $1,783,000 | $43,000 | $89,000 |
| Machinery Furniture Equipment | $816,000 | $667,000 | $199,000 | $22,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $239,931,000 | $144,559,000 | $83,977,000 | $0 |
| Construction In Progress | - | - | $0 | $42,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-133,440,000 | $-59,683,000 | $-38,070,000 | $-19,103,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-133,275,000 | $-59,172,000 | $-37,926,000 | $-19,021,000 |
| Cash Flow From Continuing Operating Activities | $-133,275,000 | $-59,172,000 | $-37,926,000 | $-19,021,000 |
| Investing Activities | ||||
| Capital Expenditure | $-165,000 | $-511,000 | $-144,000 | $-82,000 |
| Investing Cash Flow | $-93,480,000 | $-59,485,000 | $-82,842,000 | $-82,000 |
| Cash Flow From Continuing Investing Activities | $-93,480,000 | $-59,485,000 | $-82,842,000 | $-82,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $422,647,000 | $129,432,000 | $10,000,000 |
| Financing Cash Flow | $2,441,000 | $418,910,000 | $129,550,000 | $9,963,000 |
| Cash Flow From Continuing Financing Activities | $2,441,000 | $418,910,000 | $129,550,000 | $9,963,000 |
| Net Other Financing Charges | $-34,000 | $-3,896,000 | - | $-37,000 |
| Net Preferred Stock Issuance | $0 | $149,924,000 | $129,432,000 | $10,000,000 |
| Preferred Stock Issuance | $0 | $149,924,000 | $129,432,000 | $10,000,000 |
| Net Common Stock Issuance | $0 | $272,723,000 | $0 | - |
| Common Stock Issuance | $0 | $272,723,000 | $0 | - |
| Other | ||||
| End Cash Position | $101,772,000 | $326,086,000 | $25,833,000 | $17,051,000 |
| Beginning Cash Position | $326,086,000 | $25,833,000 | $17,051,000 | $26,191,000 |
| Changes In Cash | $-224,314,000 | $300,253,000 | $8,782,000 | $-9,140,000 |
| Proceeds From Stock Option Exercised | $2,475,000 | $159,000 | $118,000 | $0 |
| Net Investment Purchase And Sale | $-93,315,000 | $-58,974,000 | $-82,698,000 | $0 |
| Sale Of Investment | $292,563,000 | $231,635,000 | $46,292,000 | $0 |
| Purchase Of Investment | $-385,878,000 | $-290,609,000 | $-128,990,000 | $0 |
| Net PPE Purchase And Sale | $-165,000 | $-511,000 | $-144,000 | $-82,000 |
| Purchase Of PPE | $-165,000 | $-511,000 | $-144,000 | $-82,000 |
| Change In Working Capital | $589,000 | $1,873,000 | $-4,305,000 | $3,412,000 |
| Change In Other Current Liabilities | $-565,000 | $-133,000 | $-82,000 | $-67,000 |
| Change In Payables And Accrued Expense | $2,733,000 | $3,529,000 | $1,700,000 | $4,483,000 |
| Change In Accrued Expense | $4,014,000 | $1,512,000 | $422,000 | $4,021,000 |
| Change In Payable | $-1,281,000 | $2,017,000 | $1,278,000 | $462,000 |
| Change In Account Payable | $-1,281,000 | $2,017,000 | $1,278,000 | $462,000 |
| Change In Prepaid Assets | $-1,524,000 | $-1,008,000 | $-6,237,000 | $-585,000 |
| Change In Receivables | $-55,000 | $-515,000 | $314,000 | $-412,000 |
| Changes In Account Receivables | $-55,000 | $-515,000 | $314,000 | $-412,000 |
| Other Non Cash Items | $561,000 | $-2,677,000 | $-15,311,000 | $149,000 |
| Stock Based Compensation | $10,332,000 | $6,004,000 | $3,427,000 | $1,279,000 |
| Amortization Of Securities | $-1,502,000 | $-1,655,000 | $-1,260,000 | $0 |
| Depreciation Amortization Depletion | $188,000 | $89,000 | $60,000 | $7,000 |
| Depreciation And Amortization | $188,000 | $89,000 | $60,000 | $7,000 |
| Net Income From Continuing Operations | $-143,443,000 | $-62,806,000 | $-20,537,000 | $-23,868,000 |
| Change In Other Current Assets | - | - | $0 | $-7,000 |
Fetched: 2026-06-15